权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Wireless withdrawal detection and monitoring system for neonatal abstinence syndrome.

新生儿戒断综合征无线戒断检测和监测系统。

基本信息

批准号：
10013069
负责人：
Shiva Sharareh
金额：
$ 22.5万
依托单位：
REKOVAR INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2021-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10013069
关键词：
Accelerometer Acoustics Adult Algorithms Ambulatory Monitoring Area Biochemical Biomechanics Biometry Biosensing Techniques Biosensor Birth Blood Body Temperature Breathing Businesses Caregivers Caring Chest Computers Custom Data Data Analyses Data Engineering Dehydration Detection Development Devices Diagnosis Drug Interactions Eating Electroencephalography Event Family Funding Galvanic Skin Response Guidelines Heart Rate Hospital Costs Hospitals Hydration status Infant Intellectual Property Intervention Investigation Length of Stay Machine Learning Measures Mechanics Medical Care Costs Methodology Methods Minor Monitor Motion Neonatal Neonatal Abstinence Syndrome Neonatal Intensive Care Units Newborn Infant Nurses Opiate Addiction Patient-Focused Outcomes Patients Pattern Pediatrics Pharmaceutical Preparations Pharmacological Treatment Physiological Play Procedures Process Pulse Oximetry Reporting Research Risk Seizures Severities Skin Sleep Sneezing Substance Withdrawal Syndrome Sweating Sympathetic Nervous System Symptoms System Temperature Testing Time Toxic effect Tremor United States National Institutes of Health Validation Wireless Technology Withdrawal arm base biophysical properties care costs complex data cost experience flexibility handheld mobile device human subject improved innovation interest machine learning algorithm microchip monitoring device nanofabrication neonatal care neonate neuromuscular activity novel opioid exposure opioid withdrawal phase 1 study phase 2 study prenatal exposure printed circuit board real time monitoring response sensor therapy duration tool treatment response treatment risk wearable device wearable sensor technology

项目摘要

SPECIFIC AIMS Neonatal abstinence syndrome (NAS) is an opioid withdrawal syndrome that develops shortly after birth to in utero-exposed neonates. The cost of NAS is high: newborns with NAS are typically receive care in the Neonatal Intensive Care Unit (NICU), where the daily cost of care is high. Nearly 22,000 infants are born with NAS each year at a cost of $1.5 billion. Moreover, medication-based interventions for the treatment of NAS, used in up to 80% of opioid-exposed infants, carry their own risks of toxicity and drug interactions. Despite the medical cost, high societal impact of NAS, and the risks of treatment, the tools to assess the severity of NAS can be subjective and suffer from examiner bias. There is an urgent need for innovative new methods to diagnose NAS and assess the efficacy of responses to treatment. Flexible, low-cost wearable devices (worn on the skin) that can report measures of systemic biochemical and biomechanical processes offer a simple and economical solution. In NAS, surges of sympathetic nervous system activity produce increased heart rate, skin conductance, unstable temperature, and tremor. These manifest in increased infant sweating, seizures, tremors, unstable body temperature, and more—events that must continually monitored and assessed by nurses. The unsupervised, objective detection/quantification of the bodily response of neonates suffering from NAS could drive the development of new, objective scoring tools that can guide the initiation, intensity, and duration of therapies for NAS. Such tools could significantly reduce medical costs and improve patient outcomes by reducing patient time in NICU, reducing nurse load, improving outpatient monitoring, and helping to assist in the optimization of patient treatments. Critically, we believe such a tool may be able to objectively capture events that may go unnoticed by nurses or while the infant is sleeping (minor tremors, poor oxygenation, temperature fluctuations, dehydration). This proposal seeks to develop interlinked, infant-targeted wearable biosensor-systems capable of continuously monitoring the biochemical to biophysical parameters of opioid-dependent neonates under treatment for NAS. Our team has outstanding experience in all areas necessary to this investigation. Our business unit has extensive NIH funded experience in wearable biosensing, in the detection of sympathetic nervous system activity in opioid withdrawal, pediatrics, business development, and intellectual property. Our academic partners have broad experience in novel biosensor development.

特定的目标